Share information
247.40 €
-0.48 %
24/03/2026 17:39
-0.48 %
Open
High
Low
Volume
249.00 €
251.90 €
247.40 €
431,815
Latest News
24-Mar-2026
UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs
20-Mar-2026
Acquisition of own shares
13-Mar-2026
Share Repurchase Program 2026 to cover UCB's Long Term Incentive Plans for employees
11-Mar-2026
BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50